Maze Therapeutics, Inc. Common Stock (MAZE) — Cash Flow-to-Debt Ratio
Maze Therapeutics, Inc. Common Stock (MAZE) has a Cash Flow-to-Debt Ratio of -0.66x as of December 2025, meaning its operating cash flow of $-27.73 Million could theoretically repay -1% of its total liabilities ($42.16 Million) in one year. See Maze Therapeutics, Inc. Common Stock free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Maze Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio (2022–2025)
Historical debt coverage capacity for Maze Therapeutics, Inc. Common Stock across 4 annual periods. Also explore MAZE net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Maze Therapeutics, Inc. Common Stock (2022–2025)
Year-by-year debt coverage analysis for Maze Therapeutics, Inc. Common Stock. For market capitalisation and broader financial context, see MAZE stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.66x | $-111.94 Million | $42.16 Million | ▼ -252.5% |
| 2024 | 1.74x | $75.95 Million | $43.64 Million | ▲ +223.2% |
| 2023 | -1.41x | $-86.83 Million | $61.45 Million | ▲ +30.9% |
| 2022 | -2.04x | $-99.20 Million | $48.51 Million | — |